Genitourinary Cancer

The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer

Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.

Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.

Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.

Apalutamide plus androgen deprivation therapy (ADT) yielded a progression-free survival of 24.5 months vs 21.0 months with ADT alone.

A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.

Nivolumab bested placebo in improving disease-free survival rates in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Radioligand therapy with 177Lu-PSMA-I&T elicited favorable PSA responses and a safety profile similar to PSMA-617.

Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

An estimated 54.5% of adolescents in the United States have received the recommended doses of the HPV vaccine, although the government established a goal of an 80% vaccination rate in this population.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

The overall response rate with durvalumab and guadecitabine was 23% in patients with advanced ccRCC who had received 1 or fewer therapies.

A doublet regimen of enfortumab vedotin and pembrolizumab has received accelerated approval for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate cancer.

Lindsay Diamond, MSN, AGNP-C, AOCNP, unpacks the significance of recent advances in the bladder cancer space.

Patients with prostate cancer experienced prostate cancer-specific mortality at a low rate regardless of assigned treatment.

A combination of immune checkpoint inhibitor and MET-targeted therapy led to high responses in patients with MET-driven papillary renal cancer, although the regimen missed its primary end point.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.

Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.

Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.